5 Most Promising Gene Therapy Companies to Watch

In this piece, we will take a look at the five most promising gene therapy companies to watch. For more companies, take a look at 10 Most Promising Gene Therapy Companies to Watch.

5. Krystal Biotech, Inc. (NASDAQ:KRYS)

Market Capitalization as of November 12, 2022: $1.97 billion

Krystal Biotech, Inc. (NASDAQ:KRYS) develops treatments for rare diseases such as fibrosis, Netherton syndrome, and skin conditions. The firm is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech, Inc. (NASDAQ:KRYS)’s latest quarter saw the firm beat analyst estimates, as it posted -$0.17 in earnings per share for its third fiscal quarter. The firm is one of three companies that is developing a treatment for dystrophic epidermolysis bullosa (DEB), and the FDA has accepted the treatment’s license application alongside outlining that it will decide on the details by February next year. Krystal Biotech, Inc. (NASDAQ:KRYS)’s treatment is capable of healing full DEB wounds in six months.

Chardan raised the company’s share price target to $133 from $130 in November 2022, as it stated that several of the firm’s treatments are ready for patient dosing. The firm has a $1.97 billion market capitalization.

Krystal Biotech, Inc. (NASDAQ:KRYS)’s largest investor is Jeremy Green’s Redmile Group which owns 1.8 million shares that are worth $124 million.